Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Song Qu
Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
1 Introduction Head and neck squamous cell carcinoma (HNSCC) is a prevalent and aggressive malignancy, often linked to risk factors such as tobacco use, alcohol consumption, and human papillomavirus infection [1, 2]. Patients with recurrent or metastatic (R/M) HNSCC that cannot be treated with curative-intent therapies have a poor prognosis, despite advancements in therapeutic approaches.
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study
|
Abstract This open-label, multicenter, phase 1b/2 trial assessed the safety and efficacy of toripalimab plus cetuximab in patients with platinum-refractory (Cohort A) or previously untreated programmed cell death-ligand 1 (PD-L1)-positive (Cohort B) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Patients received toripalimab 240 mg intravenously (IV) every 3 weeks and cetuximab (400 mg/m² loading, then 250 mg/m² weekly maintenance).
By Ye Guo, Zhendong Li, Liqiong Xue, Jinguan Lin, Song Qu, Chuanzheng Sun, Meiyu Fang, Youhua Zhu, Jingfeng Zong, Wantao Chen, Guochun Cao, Jin Wu Verified, Minghua Ge, Zhiming Li, Siyang Wang, Xudong WANG, Hao Jiang, Desheng Hu, Liangfang Shen, Yumei Wei, Chuan Jin, Hong Zhi Zhang, Xiaoming Huang, Yan Sun, Jianhua Shi, Mo Wang, Xianming Luo, Rong Deng, Shijuan Kuang, Shuanghui Wei, Yuteng Shen
|
Nature
Verified
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study
|
Abstract In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks.
By Shuang Huang, Feng Liu, Song Qu, Lisha Chen, Ping Zhou, Shenhong Qu, Xiaohong Ai, Yong Chen, Meilian Liu, Rensheng Wang, Kelvin Chan Verified, Peng Zhang, Chunhong Hu, Jiyu Wen, Jian Zhang, Qin Lin, Xiaojiang Li, Kangsheng Gu, Li Xiang, Dongxia Wang, Jingao Li, Daren Lin, Desheng Hu, Jianwu Ding, Siyang Wang, Xiaoming Huang, Lin Wang, Feng Jin, David G. Pfister, Milena Perez Mak, Yi Jiang, Haihua Yang, Xiaoye Hu, Tianrun Liu, Dehua Wu, Aditya V. Shreenivas, Thiago de Oliveira, Xianming Li, Dongmei Lu, Mingxiu Hu, Zhongmin Wang, Baiyong Li, Michelle Xia, Xiaozhong Chen, Chaosu Hu, Tingting Xu, Gustavo Vasconcelos Alves, Zhifang Yao
|
Nature
Verified
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study
|
Patient characteristics Between March 2020 and July 2021, 518 patients were enrolled in this study, with 99 in phase 1 and 419 in phase 1b (Figure 1). The baseline characteristics of these participants have been previously reported.
By Yuxiang Ma, Shaoyan Lin, Qun Chen, Jinhui Xue, Yunpeng Yang, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen, Song Qu, Jianbo He, Chuanben Chen, Chuan Jin, Dongyuan Zhu, Qingshan Li, Xianling Liu, Wuyun Su, Yi Ba, Weiwei Li, Qian Li, Changbin Zhu, Zhan Huang, Xiaoyan Kang, Hui Li, Chao Wang, Fan Luo, Yan Huang, Li Zhang, Hongyun Zhao, Shilin Xue
|
Cell Reports Medicine
Verified
Development and validation of a neutrophil percentage-to-albumin ratio
Back to Journals » Journal of Inflammation Research » Volume 19 Original Research Onco-inflammation Authors Yang X, Huang L, Qu S Received 26 September 2025 Accepted for publication 26 January 2026 Published 5 February 2026 Volume 2026:19 Pages 1—20 DOI https://doi.org/10.2147/JIR.S566289 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Subhasis Chattopadhyay Xiaohui Yang,1 Lu Huang,2 Song Qu1 1Department of...
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Summary Background The addition of camrelizumab to gemcitabine and cisplatin showed promising activity as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma in a phase 1 trial. We therefore compared camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin in a randomised phase 3 trial.
Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma
Loading metrics Open Access Peer-reviewed Research Article Xin-Bin Pan, Shi-Ting Huang, Song Qu, Kai-Hua Chen, Yan-Ming Jiang, Xiao-Dong Zhu Xin-Bin Pan, Shi-Ting Huang, Song Qu, Kai-Hua Chen, Yan-Ming Jiang, Xiao-Dong Zhu Published: June 17, 2021 https://doi.org/10.1371/journal.pone.0253424 Figures Abstract Purposes To evaluate retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma (NPC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Song
Contact Song, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack